Yale Clinical Metabolism Core


Stable isotopes offer unique advantages over traditional radioisotopic methods for assessing substrate turnover in humans in that they do not expose subjects to ionizing radiation and they provide positional isotopomer information, which in turn, can be used to assess flux thru critical metabolic pathways. The major disadvantage to the clinical investigator is that they require highly skilled expertise and expensive analytical equipment for their analysis. The Yale-DRC Clinical Metabolism Core overcomes these limitations by providing the personnel, methodology, and instrumentation for the centralized analysis of stable isotopic enrichment of biochemical compounds using state-of-the-art Gas Chromatographic-Mass Spectrometric (GC-MS), Liquid Chromatographic-Mass Spectrometric-Mass Spectrometric (LC-MS-MS) and nuclear magnetic resonance spectroscopy (NMR) spectroscopic methods. This core measures isotopic enrichments in metabolites (amino acids, glucose, glycogen, urea, and glucuronide conjugates) purified from plasma, urine or tissues by ion exchange chromatography, by: 13C, 1H or 31P NMR spectroscopy or combined GC-MS or LC-MS-MS analysis.


The primary purpose of the Yale-DRC Clinical Metabolism core is to:

  • to make GC-MS, LC-MS-MS and NMR analyses available to DRC participants,
  • to save money and effort by reducing duplication of personnel required to program and operate the spectrometers,
  • to provide standardized procedures to insure the accuracy of sample analysis and
  • to assist DRC participants in the design and interpretation of experiments which require GC-MS, LC-MS-MS or NMR analysis.

Core People

Core Director
Gerald I Shulman Gerald I Shulman MD PhD Yale Clinical Metabolism Core Email